Posts

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

on

MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies

on

Placebo Response Trips Up Harmony Biosciences’ Fragile X Drug in Late-Stage Phase 3 Trial

on

FDA Rejection Derails PTC Therapeutics' Rare Disease Hopeful

on

Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

on

Spine BioPharma's Phase 3 Back Pain Drug Fails to Meet Primary Endpoint, Attributes Miss to High Sham Response

on

FDA Rejects Capricor's Cell Therapy for Duchenne Muscular Dystrophy

on

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

on

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

on

FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray for PSVT

on

Gilead's Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment

on

RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses

on